Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC trimmed its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 40.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,306,220 shares of the company's stock after selling 870,977 shares during the quarter. Janus Henderson Group PLC owned approximately 1.30% of Day One Biopharmaceuticals worth $16,556,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth about $866,000. MetLife Investment Management LLC grew its holdings in shares of Day One Biopharmaceuticals by 12.4% during the fourth quarter. MetLife Investment Management LLC now owns 34,248 shares of the company's stock worth $434,000 after purchasing an additional 3,781 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Day One Biopharmaceuticals by 90.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company's stock valued at $1,535,000 after purchasing an additional 57,601 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Day One Biopharmaceuticals by 5.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company's stock worth $6,785,000 after buying an additional 28,053 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Day One Biopharmaceuticals by 43.4% during the fourth quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company's stock worth $3,102,000 after acquiring an additional 74,091 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company's stock.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN traded up $0.23 on Monday, hitting $6.48. The company's stock had a trading volume of 1,811,522 shares, compared to its average volume of 1,107,801. Day One Biopharmaceuticals, Inc. has a 12-month low of $6.08 and a 12-month high of $16.76. The company has a market capitalization of $656.83 million, a price-to-earnings ratio of -6.29 and a beta of -1.24. The stock has a 50 day moving average of $7.44 and a 200-day moving average of $10.77.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analyst estimates of $30.28 million. Sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Jeremy Bender sold 13,964 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $87,414.64. Following the transaction, the chief executive officer now directly owns 145,737 shares of the company's stock, valued at $912,313.62. The trade was a 8.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel Adam Dubow sold 4,646 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the transaction, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. The trade was a 10.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,789 shares of company stock valued at $419,224 in the last quarter. 6.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DAWN. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. JPMorgan Chase & Co. cut their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. Wedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC dropped their price objective on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $30.57.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.